Key facts
- Hylomorph’s last known valuation is $25.0M (Jul 2023).
- It has raised $18.1M; the latest was Later Stage VC in May 2025.
- Notable investors include European Innovation Council, Venture Kick, European Commission, Verve Ventures, Zürcher Kantonalbank — 16 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 16 names
- ·Watchlist + deal alerts for Hylomorph
- ·The full record, as it builds
Funding rounds
No funding rounds for Hylomorph are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Hylomorph
Manufacturer of healthcare biomaterials intended to optimize the interface between implantable medical devices and biological tissues. The company's bio-engineered implants prevent postoperative complications in implantable medical devices such as fibrosis, infection, and migration, deploy advanced methods combining biotech and surface micro-engineering to promote optimal interaction between human tissues and foreign implants and first indication for use in cardiac pacemakers, defibrillators and neurostimulators, enabling doctors to improve the quality of life of patients and the quality of care by healthcare professionals.
- Sector
- Healthcare
- HQ
- Zurich, Switzerland
- Founded
- 2014
- Employees
- 11
- Website
- hylomorph-medical.com/
- Ownership
- Privately Held (backing)
Hylomorph doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Hylomorph shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Hylomorph in its N-PORT filings yet. We sweep new filings monthly.